Intellia Therapeutics Downgraded to Neutral by Chardan, Price Target Kept at $20/Share

Intellia Therapeutics Downgraded to Neutral by Chardan, Price Target Kept at $20/Share

Intellia Therapeutics (NTLA) received an investment-rating downgrade Tuesday to neutral from buy from Chardan Capital Markets, which cited the outperformance this year of the genome-editing company’s shares versus peers while saying the firm still has a positive bias on the stock. Chardan kept its price target on the shares at $20 per share, which is slightly below the stock’s Monday closing price of $20.82. The shares jumped 19% in Monday’s […]

Read More ˃